[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100561248":3},{"organization":4,"armGroups":7,"interventions":23,"overallOfficials":40,"centralContacts":45,"locations":52,"responsibleParty":70,"collaborators":50,"id":72,"slug":73,"hasResults":74,"nctId":75,"briefTitle":76,"officialTitle":76,"acronym":50,"eligibilityCriteria":77,"healthyVolunteers":74,"sex":78,"minAge":79,"maxAge":80,"enrollmentInfo":81,"targetDuration":50,"studyType":84,"phases":85,"briefSummary":87,"conditions":88,"keywords":50,"overallStatus":54,"whyStopped":50,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":99},{"fullName":5,"class":6},"Peking University Third Hospital","OTHER",[8,13,18],{"label":9,"type":6,"description":10,"interventionNames":11},"Sitagliptin","100mg\u002Fday Sitagliptin by oral for 3 months\n\ndetail：1 piece(100mg) at morning",[12],"Drug: Sitagliptin",{"label":14,"type":6,"description":15,"interventionNames":16},"BeiDouGen","120mg\u002Fday BeiDouGen capsule by oral for 3 months\n\ndetail：2 piece(30mg) at morning and night",[17],"Drug: BeiDouGen",{"label":19,"type":6,"description":20,"interventionNames":21},"Sitagliptin+BeiDouGen","100mg\u002Fday Sitagliptin+120mg\u002Fday BeiDouGen capsule by oral for 3 months\n\ndetail：1 piece(100mg) Sitagliptin and 2 piece(30mg) BeiDouGen capsule at morning 2 piece(30mg) BeiDouGen capsule at night",[22],"Drug: Sitagliptin+BeiDouGen",[24,30,35],{"type":25,"name":9,"description":26,"armGroupLabels":27,"otherNames":28},"DRUG","100 mg QD for 3 month",[9],[29],"brand name:Jie Nuo Wei",{"type":25,"name":14,"description":31,"armGroupLabels":32,"otherNames":33},"60 mg BID for 3 month",[14],[34],"brand name:Kang xin",{"type":25,"name":19,"description":36,"armGroupLabels":37,"otherNames":38},"100 mg Sitagliptin QD plus BeiDouGen 60 mg BID for 3 month",[19],[39],"brand name:Jie Nuo Wei and Kang xin",[41],{"name":42,"affiliation":43,"role":44},"Jie Qiao","the third hospital of peking universry","STUDY_CHAIR",[46],{"name":47,"role":48,"phone":49,"phoneExt":50,"email":51},"Jie Qiao, PhD","CONTACT","15611555481",null,"myl1995lmy@163.com",[53],{"facility":5,"status":54,"city":55,"state":56,"zip":57,"country":58,"countryCode":59,"cosmosGeoPoint":60,"geoPoint":65,"contacts":66},"RECRUITING","Beijing","Beijing Municipality","100000","China","CN",{"type":61,"coordinates":62},"Point",[63,64],116.39723,39.9075,{"lat":64,"lon":63},[67],{"name":42,"role":48,"phone":68,"phoneExt":50,"email":69},"010-82265080","jie.qiao@263.net",{"type":71,"investigatorFullName":50,"investigatorTitle":50,"investigatorAffiliation":50,"oldNameTitle":50,"oldOrganization":50},"SPONSOR","100561248","sitagliptin-or-beidougen-capsule-improve-the-pregnancy-outcome-in-patients-with-pcos-100561248",false,"NCT06587698","Sitagliptin or BeiDouGen Capsule Improve the Pregnancy Outcome in Patients with PCOS","Inclusion Criteria:\n\n* Female patients aged 20-40 years who plan to conceive or are infertile in our center.\n\nDiagnosed with PCOS according to the Rotterdam criteria: Diagnosis of PCOS can be made if two out of the following three criteria are met: (1) Oligoovulation or anovulation, (2) Clinical or biochemical signs of hyperandrogenism, (3) Polycystic ovaries on ultrasound examination.\n\nPatients who are regularly followed up at our clinic. No participation in other research projects currently or in the past 3 months.\n\nExclusion Criteria:\n\nExclusion criteria (any of the following criteria met will result in exclusion):\n\nPregnant, lactating, or postmenopausal women. Taking weight loss medications or undergoing weight loss surgery in the past 3 months or currently.\n\nFood allergies. Other diseases that may cause hyperandrogenism or ovulation abnormalities (e.g., Cushing's syndrome, non-classical congenital adrenal hyperplasia, tumors secreting androgens in the ovaries or adrenal glands, functional hypothalamic amenorrhea, thyroid diseases, hyperprolactinemia, premature ovarian insufficiency, etc.).\n\nUse of insulin, hypoglycemic drugs, or beta-blockers in the past 3 months. Patients with chronic diseases such as hypertension, gout, hyperuricemia, diabetes, etc., requiring regular medication.\n\nUse of glucocorticoids, anti-androgenic drugs, oral contraceptives, ovulation-inducing drugs, weight loss drugs, or other medications affecting hormone levels, appetite, and carbohydrate metabolism in the past 2 months.\n\nPatients with liver cirrhosis or various severe liver diseases (alanine aminotransferase and\u002For aspartate aminotransferase exceeding 3 times the upper limit of normal), patients with abnormal renal function (serum creatinine exceeding the upper limit of normal), patients with kidney disease or other diseases requiring control of protein intake.\n\nPatients currently or previously with severe cardiovascular and cerebrovascular diseases that may interfere with the normal conduct of the trial (such as heart failure, myocardial infarction, cerebral infarction, acute myocarditis, severe arrhythmias, patients undergoing interventional therapy, etc.).\n\nPatients currently with severe gastrointestinal diseases such as gastrointestinal ulcer bleeding, chronic diarrhea, or who have undergone gastrointestinal resection surgery, which may affect nutrient absorption.\n\nPatients with infectious diseases such as hepatitis B e antigen-positive, active pulmonary tuberculosis, or HIV.\n\nCancer patients or those who have received radiation and chemotherapy within the past five years.\n\nPatients with any psychological or psychiatric disorders requiring medication, including epilepsy patients or those undergoing antiepileptic treatment, patients using antidepressants, etc.\n\nDaily alcohol consumption exceeding 15g. Smoking habit\n\n\\-","FEMALE","20 Years","40 Years",{"count":82,"type":83},300,"ESTIMATED","INTERVENTIONAL",[86],"NA","This study will be carried out under the guidance of professional doctor, patients with PCOS will be treated with Sitagliptin or BeiDouGen capsule or both two to assess their ovarian function and reproductive outcomes, and compare the effect of different treatment methods, which will provide the basis for PCOS intervention strategy and related research",[89],"Polycystic Ovarian Syndrome","2024-09-04",{"date":92,"type":93},"2024-09-19","ACTUAL",{"date":95,"type":93},"2024-08-21",{"date":97,"type":83},"2029-07-01",{"name":5,"class":6},1]